## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION** Washington, D.C. 20549

FORM 8-K

### **CURRENT REPORT** Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2010

# LifeVantage Corporation (Exact name of registrant as specified in its charter)

	Colorado	000-30489	90-0224471	
	(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)	
11545 W. Bernardo Court, Suite 301, San Diego, California			92127	
	(Address of Principal Executive O	ttices)	(Zip Code)	
	Registi	ant's telephone number, including area code:	: (858) 312-8000	
	(Fo	rmer name or former address if changed sinc	e last report.)	
	eck the appropriate box below if the Form 8-K fivisions:	ling is intended to simultaneously satisfy the	filing obligation of the registrant under any of the following	
0	Written communications pursuant to Rule 425	under the Securities Act (17 CFR 230.425)		
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
0	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
0	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			

#### **Item 2.02** Results of Operations and Financial Conditions

On November 9, 2010, Lifevantage Corporation issued a press release announcing its unaudited first quarter fiscal 2011 financial and operating results. The press release is furnished as Exhibit 99.1 hereto and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

#### Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated November 9, 2010.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 9, 2010 LifeVantage Corporation

By: /s/ Carrie E. McQueen

Carrie E. McQueen

Chief Financial Officer, Secretary & Treasurer



#### LIFEVANTAGE ANNOUNCES UNAUDITED FIRST QUARTER FISCAL 2011 FINANCIAL AND OPERATING RESULTS

Company Reports \$345k Record Operating Profit on Revenue Increase of \$4.6 million, or 247% over Same Quarter Last Year

Conference call scheduled for November 10, 2010 at 1:30pm (Pacific); simultaneous webcast at <a href="https://www.lifevantage.com">www.lifevantage.com</a>

San Diego, CA, November 9, 2010, LifeVantage Corporation (OTCBB: LFVN), the maker of science-based solutions to oxidative stress, announced unaudited first quarter fiscal 2011 financial and operating results.

The Company recorded approximately \$6.4 million net revenue for the three month period ended September 30, 2010, which represents a \$4.6 million, or 247%, increase over net revenue from the same quarter last fiscal year, and a \$2.0 million, or 45%, sequential increase over net revenue from the fourth fiscal quarter of 2010. The Company also recorded \$5.4 million in gross profit, representing an 84% gross profit margin, an approximate 1% improvement over both first and fourth fiscal quarters of 2010.

Total operating expenses for the first fiscal quarter 2011 were approximately \$5.1 million, which represents a \$525,000, or 12%, increase over operating expenses from the same quarter last fiscal year, and a \$1.1 million, or 27%, sequential increase over operating expenses from the fourth fiscal quarter of 2010. The increase of \$1.1 million over last quarter is due to increased sales commissions attributed directly to increased revenue, and to higher personnel costs, tied to our increased support requirements.

Along with recording our highest quarterly net revenue of \$6.4 million, the Company is also reporting record operating income of approximately \$345,000 in the first fiscal quarter 2011. This \$345,000 operating profit compares to an operating loss of over \$3.0 million for the same quarter last year and an operating loss of \$290,000 for the most recent fourth fiscal quarter 2010. The improvement of \$635,000 in operating income is due to a \$1.7 million increase in gross profit offset by a \$1.1 million increase in operating expenses.

"We are very pleased with our first quarter results," said David W. Brown, LifeVantage President and CEO, "They reflect the growth we saw at our recent Elite Academy in San Diego, attended by over 1200 distributors. We'd like to thank all of our distributors, customers and employees responsible for these record results."

#### **Conference Call Information**

The Company will hold a conference call on November 10, 2010 at 1:30pm Pacific time (4:30pm Eastern time) to discuss first fiscal quarter 2011 financial and operating results and provide an update on its business. David W. Brown, President and Chief Executive Officer, is scheduled to lead the call and will be joined by Carrie E. McQueen, Chief Financial Officer.

The conference call may be accessed by dialing 888-452-4034 for domestic callers and entering the pass code 2457343. The webcast will be available live via the Internet by accessing the Investors section of LifeVantage's website at <a href="http://www.lifevantage.com/investor-profile.aspx">http://www.lifevantage.com/investor-profile.aspx</a>. Replays of the webcast will be available on LifeVantage's website for 30 days and a phone replay will be available through November 15th, 2010 by dialing 888-203-1112 and entering the pass code 2457343.

#### **About LifeVantage Corporation**

LifeVantage Corporation (OTCBB: LFVN) is a dietary supplement company which markets and sells its products through the network marketing, or multi-level marketing industry, and seeks to enhance life through anti-aging and wellness products while creating business opportunities. The Company offers only what it refers to as "true" products, which are products backed by science, in two principal categories: a dietary supplement that combats oxidative stress and anti-aging skincare. LifeVantage's centerpiece product is Protandim®, a dietary supplement which has been clinically proven to reduce the effects of oxidative stress as well as the progressive rate of cellular aging. The Company also offers LifeVantage TrueScience<sup>TM</sup> Anti-Aging Cream, a scientifically-based, groundbreaking and unique skin care product. For more information, visit <a href="https://www.LifeVantage.com">www.LifeVantage.com</a>.



#### **Forward Looking Statements**

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the potential failure or unintended negative consequences of the implementation of the Company's network marketing sales channel; the Company's ability to retain independent distributors or to attract new independent distributors on an ongoing basis; the potential for third party and governmental actions involving the Company's network marketing sales channel; the potential for product liability claims against the Company; the risk that government regulators and regulations could adversely affect the Company's business; future laws or regulations may hinder or prohibit the production or sale of the Company's existing product and any future products; unfavorable publicity could materially hurt the Company's business; and the Company's ability to protect its intellectual property rights and the value of its product. These and other risk factors are discussed in greater detail in the Company's Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption "Risk Factors", and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

###

#### **Investor Relations Contact:**

Ioana C. Hone (858) 312-8000 Ext. 4

# LIFEVANTAGE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

		For the three months ended September 30,	
	2010	2009	
Sales, net	\$ 6,443,349	\$ 1,857,997	
Cost of sales	1,020,135	312,974	
Gross profit	5,423,214	1,545,023	
Operating expenses:			
Sales and marketing	3,410,843	2,012,166	
General and administrative	1,507,093	2,381,156	
Research and development	109,793	106,892	
Depreciation and amortization	50,716	53,298	
Total operating expenses	5,078,445	4,553,512	
Operating income (loss)	344,769	(3,008,489)	
Other income (expense):			
Interest expense	(1,464,623)	(153,701)	
Change in fair value of derivative liabilities	1,835,047	6,027,736	
Total other income	370,424	5,874,035	
Net income	715,193	2,865,546	
	<del></del>		
Net income per share, basic and diluted	\$ 0.01	\$ 0.05	
Weighted average shares, basic	63,684,437	55,634,601	
Weighted average shares, diluted	89,693,864	61,841,866	